Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
NCT05661201Phase 1Recruiting
- Sponsor
- Georgetown University
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nerofe in solid tumor (5 arms), sponsored by Georgetown University. Primary endpoints: Incidence of adverse events at 6 months, Incidence of Serious Adverse events at 6 months and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
nerofe
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05661201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661201.